Caribou Biosciences (CRBU) AI Stock Analysis

• Market Cap: $151.60M
• Dividend Yield: N/A
• Average Volume (3M): 1.67M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.50
• Revenue Growth: -70.31%
• EPS Growth: -11.68%
• Country: US
• Employees: 147
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.43
• Shares Outstanding: 93,004,600
• 10 Day Avg. Volume: 1,331,852
• 30 Day Avg. Volume: 1,673,366
• PEG Ratio: -0.59
• Price to Book (P/B): 0.73
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.11
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 2.40
• Enterprise Value/Gross Profit: 19.66
• Enterprise Value/Ebitda: -0.25
• 1Y Price Target: $5.20
• Price Target Upside: 205.88% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 55 Neutral
• Price Target: $1.50 ▼(-11.76%Downside)

The overall stock score reflects significant financial challenges and valuation concerns, balanced by positive technical indicators and a notable corporate event. Regaining Nasdaq compliance and favorable analyst sentiment provide a measure of confidence, but the company's financial health needs improvement for sustainable growth.

Positive Factors

Clinical Development

CRBU plans to share pivotal design and timeline based on FDA feedback for CB-010 in 2L LBCL, contingent on positive data, indicating a potential step forward in clinical development.

Financial Position

Caribou's management anticipates that its $212.5 million war chest shall provide an operational runway extending into the second half of 2027, reflecting financial stability.

Valuation

Analyst continues to consider Caribou undervalued and believes that the company's current situation involves a much more favorable position from which to weather equity capital markets volatility.

Negative Factors

Approval Probability

There is a low probability of approval for both CB-010 at 30% and CB-011 at 20%, raising concerns over the success rate of upcoming clinical trials.

Clinical Risks

Risks include negative clinical results with the company's lead assets, delays in advancing these candidates into registrational programs, and failure to achieve favorable clinical results with other pipeline candidates.

Pipeline Risks

The discontinuation of CB-010 in lupus, CB-012 in AML, and preclinical research reduces the value from the pipeline, impacting the company's long-term growth prospects.

Caribou Biosciences Business Overview & Revenue Model

Company Description

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

How the Company Makes Money

Caribou Biosciences generates revenue primarily through partnerships, collaborations, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve joint research and development efforts or the licensing of Caribou's proprietary CRISPR technology. Additionally, the company may receive milestone payments and royalties associated with the successful development and commercialization of products resulting from these collaborations. Caribou's revenue model is significantly influenced by its ability to advance its technology platform and establish strategic partnerships to leverage its genome editing capabilities in therapeutic settings.

Caribou Biosciences Financial Statement Overview

Summary

Caribou Biosciences faces challenges with declining revenues, substantial operational losses, and negative cash flows, which overshadow its strong equity position and low leverage ratio. The company needs to address revenue growth and operational efficiency to improve financial health and sustainability.

Income Statement

Caribou Biosciences shows declining revenue, with the TTM (Trailing-Twelve-Months) revenue at $9.918 million compared to $34.477 million the previous year, indicating a significant drop. The gross profit margin for TTM is approximately 79.41%, suggesting high efficiency in cost management relative to revenue. However, the company is struggling with significant losses as evidenced by the negative net profit margin and EBIT margin, with a TTM net income of -$147.862 million. These figures reflect challenges in scaling revenue while controlling operational costs.

Balance Sheet

The company maintains a solid equity base with a stockholders' equity of $217.222 million in the TTM period. The debt-to-equity ratio stands at 0.12, indicating low leverage and a conservative capital structure. However, the ROE is negative due to the company's net losses, impacting profitability. The equity ratio is relatively strong, suggesting a healthy buffer of equity relative to total assets. Despite the strengths in capital structure, consistent losses pose a risk to long-term financial stability.

Cash Flow

Cash flow analysis reveals negative free cash flow and operating cash flow, with TTM free cash flow at -$142.196 million, indicating cash strain from operations. The ratio of operating cash flow to net income is less than 1, highlighting inefficient cash conversion. Though the company has substantial cash reserves, the negative cash flow trends point to potential liquidity issues if losses persist without external financing or revenue improvement.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.99M	34.48M	13.85M	9.60M	12.36M
Gross Profit	6.07M	-77.60M	10.21M	8.61M	-22.06M
EBITDA	-166.62M	-112.53M	-104.78M	-66.00M	-35.21M
Net Income	-149.10M	-102.07M	-99.42M	-66.92M	-34.31M
Balance Sheet
Total Assets	313.31M	432.21M	373.76M	442.36M	36.05M
Cash, Cash Equivalents and Short-Term Investments	209.54M	328.83M	317.04M	413.51M	15.95M
Total Debt	26.49M	27.11M	27.75M	259.00K	1.58M
Total Liabilities	60.36M	63.81M	72.89M	54.53M	59.48M
Stockholders Equity	252.95M	368.40M	300.87M	387.82M	-23.44M
Cash Flow
Free Cash Flow	-143.08M	-104.90M	-98.02M	-35.64M	-34.53M
Operating Cash Flow	-138.20M	-93.29M	-90.97M	-32.52M	-33.22M
Investing Cash Flow	86.61M	-68.18M	-93.25M	-176.40M	6.36M
Financing Cash Flow	16.72M	154.30M	2.13M	433.43M	1.74M

Caribou Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.70
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBU, the sentiment is Positive. The current price of 1.7 is above the 20-day moving average (MA) of 1.42, above the 50-day MA of 1.17, and above the 200-day MA of 1.45, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 62.55 is Neutral, neither overbought nor oversold. The STOCH value of 74.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRBU.

Caribou Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EDIT	66 Neutral	$241.09M	―	-140.82%	―	-48.37%	-44.70%
CRBU	55 Neutral	$151.60M	―	-52.76%	―	-70.31%	-11.68%
Sector *	52 Neutral	$7.53B	0.20	-63.81%	2.31%	16.15%	0.40%
MGNX	49 Neutral	$99.68M	―	-60.25%	―	255.31%	-141.39%
VXRT	44 Neutral	$98.17M	―	-114.74%	―	433.43%	49.04%
ZURA	43 Neutral	$80.44M	―	-62.34%	―	―	86.65%
ELTX	30 Underperform	$143.97M	―	-744.59%	―	―	27.65%

Caribou Biosciences Corporate Events

Caribou Biosciences Regains Nasdaq Compliance

On June 18, 2025, Caribou Biosciences announced that it had regained compliance with Nasdaq’s listing requirements, specifically maintaining a minimum closing bid price of $1.00 per share. This compliance, achieved between June 3 and June 17, 2025, ensures the company’s continued listing on the Nasdaq Global Select Market, which is crucial for its market presence and investor confidence.

The most recent analyst rating on (CRBU) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Caribou Biosciences stock, see the CRBU Stock Forecast page.

Caribou Biosciences Confirms Director Elections and Auditor

On June 12, 2025, Caribou Biosciences, Inc. held its annual meeting of stockholders, where several key proposals were voted on. The election of two Class I directors, Scott Braunstein, M.D. and Ran Zheng, M.S., was confirmed, and the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, stockholders approved an amendment to the company’s certificate of incorporation to allow a reverse stock split and the potential adjournment of the annual meeting if necessary, although the latter was not needed as there was a quorum and sufficient votes for the proposals.

The most recent analyst rating on (CRBU) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Caribou Biosciences stock, see the CRBU Stock Forecast page.